Notices. Notice
200 words·~1 min read·
/register/2002/05/16/02-12181·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 3710-08-M DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Assay for the Proteolytic Activity of Serotype A Neurotoxin From Clostridium Botulinum AGENCY: Department of the Army, DOD. ACTION: Notice. SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 5,965,699 entitled “Assay for the Proteolytic Activity of Serotype A Neurotoxin from Clostridium Botulinum” issued October 12, 1999.
The United States Government, as represented by the Secretary of the Army has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney,
(301)619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment,
(301)619-6664, both at telefax
(301)619-5034. SUPPLEMENTARY INFORMATION: A label-based assay is described , through modifications of substrate structure and derivatization of serum albumin, which can be used to determine type A proteolytic activity without separation of products. Luz D. Ortiz, Army Federal Register Liaison Officer. [FR Doc. 02-12181 Filed 5-15-02; 8:45 am]
Connectionstraces to 1
Traces to 1 document